Boehringer Ingelheim International Gmbh

Centrexion Therapeutics Corporation

Boehringer Ingelheim Pharmaceuticals, Inc.

Doris Riether

Renee M Zindell

Eugene R Hickey

David S Thomson

Monika Ermann

Lifen Wu

Alessandra Bartolozzi

Janet Rachel Nicholson

Angela Kay Berry

Innocent Mushi

Achim Sauer

Nigel James Blumire

Niklas Heine

Uta Friederike Lessel

Pier Francesco Cirillo

Marco Ferrara

Florian Paul Christian Binder

Henri Doods

Stephan Georg Mueller

Anton Pekcec

Heather Tye

Zhidong Chen

Pui Leng Loke

Someina Khor

James Edward Jenkins

Weimin Liu

Todd Bosanac

Daniel Kuzmich

Hossein Razavi

Stefan Scheuerer

Ho Yin Lo

Stephane De Lombaert

Ji Wang

John D Huber

Patricia Amouzegh

Christopher Francis Palmer

Alan Olague

Christian Hanke Justus Joachim Harcken

Tina Marie Morwick

Thomas A Gilmore

Stephen East

Rajashehar Betageri

Jonathon Alan Dines

Malcolm Taylor

John Robert Proudfoot

Hidenori Takahashi

Markus Ostermeier

Younes Bekkali

Rajashekhar Betageri

Thorsten K Oost

John R Regan

Wolfgang Wienen

Stefan Peters

Alexander Pautsch

Mario G Cardozo

Thomas Martin Kirrane, Jr

Marc Grundl

Heiner Ebel

Abdelhakim Hammach

Dirk Gottschling

Usha R Patel

Michel Jose Emmanuel

Peter Allen Nemoto

Bernd Wellenzohn

Pingrong Liu

Stéphane De Lombaert

Robert John Scott

Thomas Wai-Ho Lee

Radoslaw Lipinski

Eugene Richard Hickey

Chandana Chowdhury

Henri Doobs

Stephan George Mueller

Thomas Martin Kirrane

Chandana Parke

Edward Thomas Glenn

Przemyslaw Zawadzki

Florian Binder

Uta Lessel

Nigel Ermann

Edward Glenn

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

(cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

The present invention relates to novel N-(2,2-difluoroethyl)-N-[(Pyrimidinylamino)propanyl]-arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)-propanyl]- and N-[(Pyrazinylamino)&#xac;propanyl]arylcarboxamide such as compound  The present invention also relates to derivatives of such compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, R, R, R, R, Rand Rhave meanings given in the description. 

N-[(pyridyloxy)propanyl]benzamides

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Arand Arhave meanings given in the description. 

N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides

This invention relates to compounds of formula I a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, Rand Rhave meanings given in the description.

N-[(pyrazinyloxy)propanyl]benzamides as antagonists of orexin subtype 1 receptor activity

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, R, R, R, Rhave meanings given in the description. 

N-[(pyrimidinyloxy)propanyl]benzamides

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazolesand-[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. 

Compounds which modulate the CB2 receptor

Growing community of inventors

Biberach an der Riss, Germany

Doris Riether